Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Variant||EML4 - NTRK3|
|Protein Effect||gain of function|
|Gene Variant Descriptions||EML4-NTRK3 results from the fusion of EML4 and NTRK3 and leads to transformation of cultured cells and activation of MAPK signaling in a reporter assay (PMID: 30279230). EML4-NTRK3 has been identified in MSI-high colorectal cancer (PMID: 30279230).|
|Associated Drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|EML4 - NTRK3||thyroid gland papillary carcinoma||predicted - sensitive||Entrectinib||Case Reports/Case Series||Actionable||In a clinical case study, a patient with papillary thyroid carcinoma harboring EML4-NTRK3 demonstrated a 69.7% decrease in disease burden after 34 cycles of treatment with Rozlytrek (entrectinib) (PMID: 32457407).||32457407|
|EML4 - NTRK3||malignant glioma||predicted - sensitive||Crizotinib||Preclinical - Cell culture||Actionable||In a preclinical study, treatment with Xalkori (crizotinib) resulted in inhibition of cell growth in a glioma cell line harboring EML4-NTRK3 in culture (PMID: 25485619).||25485619|
|EML4 - NTRK3||Advanced Solid Tumor||predicted - sensitive||Entrectinib||Case Reports/Case Series||Actionable||In a Phase Ib/II trial (STARTRK-NG), a patient with an advanced solid tumor harboring EML4-NTRK3 demonstrated a partial response when treated with Rozlytrek (entrectinib) (Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020) 107-107; NCT02650401).||detail...|
|EML4 - NTRK3||Advanced Solid Tumor||predicted - sensitive||Entrectinib||Preclinical - Cell culture||Actionable||In a preclinical study, Rozlytrek (entrectinib) inhibited growth of transformed cells expressing EML4-NTRK3 in culture (PMID: 30279230).||30279230|